In this study, serum SV2A levels were significantly lower in cognitively unimpaired APOE ε4 carriers than in cognitively unimpaired non-carriers before and after adjusting for age and sex, suggesting that serum SV2A levels had already decreased during the preclinical phase of AD. This evidence concerns the gene APOE and Alzheimer disease.